Latest period
$90.1B
YoY change
-2.0%
5Y CAGR
+6.5%
Peak year (FY2022)
$95.7B
Latest annual
$86.5B
Total Equity history chart for Pfizer (PFE) from 2016 to 2025
Latest: $86.5B
Total Equity growth chart for Pfizer (PFE) from 2016 to 2025
Latest: -2.0%
Total Equity history table for Pfizer (PFE) from 1985 to 2025
| FY2025 | $86.5B | -2.0% | -$1.73B | ||
| FY2024 | $88.2B | -0.9% | -$811M | ||
| FY2023 | $89B | -6.9% | -$6.65B | ||
| FY2022 | $95.7B | +23.9% | +$18.5B | ||
| FY2021 | $77.2B | +22.1% | +$14B | ||
| FY2020 | $63.2B | +0.2% | +$95M | ||
| FY2019 | $63.1B | -0.4% | -$264M | ||
| FY2018 | $63.4B | -11.1% | -$7.9B | ||
| FY2017 | $71.3B | +19.8% | +$11.8B | ||
| FY2016 | $59.5B | -8.0% | -$5.18B | ||
| FY2015 | $64.7B | -9.2% | -$6.58B | ||
| FY2014 | $71.3B | -6.6% | -$5.01B | ||
| FY2013 | $76.3B | -6.1% | -$4.95B | ||
| FY2012 | $81.3B | -1.1% | -$930M | ||
| FY2011 | $82.2B | -6.4% | -$5.62B | ||
| FY2010 | $87.8B | -2.4% | -$2.2B | ||
| FY2009 | $90B | +56.4% | +$32.5B | ||
| FY2008 | $57.6B | -11.5% | -$7.45B | ||
| FY2007 | $65B | -8.9% | -$6.35B | ||
| FY2006 | $71.4B | +8.7% | +$5.73B | ||
| FY2005 | $65.6B | -3.9% | -$2.65B | ||
| FY2004 | $68.3B | +4.4% | +$2.9B | ||
| FY2003 | $65.4B | +227.7% | +$45.4B | ||
| FY2002 | $20B | +9.1% | +$1.66B | ||
| FY2001 | $18.3B | +13.8% | +$2.22B | ||
| FY2000 | $16.1B | +80.9% | +$7.19B | ||
| FY1999 | $8.89B | +0.9% | +$77M | ||
| FY1998 | $8.81B | +11.1% | +$877M | ||
| FY1997 | $7.93B | +14.1% | +$979M | ||
| FY1996 | $6.95B | +26.3% | +$1.45B | ||
| FY1995 | $5.51B | +27.4% | +$1.18B | ||
| FY1994 | $4.32B | +11.9% | +$458M | ||
| FY1993 | $3.87B | -18.1% | -$853M | ||
| FY1992 | $4.72B | -6.1% | -$308M | ||
| FY1991 | $5.03B | -1.3% | -$65.7M | ||
| FY1990 | $5.09B | +12.3% | +$556M | ||
| FY1989 | $4.54B | +5.5% | +$235M | ||
| FY1988 | $4.3B | +10.8% | +$419M | ||
| FY1987 | $3.88B | +13.7% | +$467M | ||
| FY1986 | $3.42B | +16.7% | +$488M | ||
| FY1985 | $2.93B | — | — |
- FY2025$86.5B-2.0%
- FY2024$88.2B-0.9%
- FY2023$89B-6.9%
- FY2022$95.7B+23.9%
- FY2021$77.2B+22.1%
- FY2020$63.2B+0.2%
- FY2019$63.1B-0.4%
- FY2018$63.4B-11.1%
- FY2017$71.3B+19.8%
- FY2016$59.5B-8.0%
- FY2015$64.7B-9.2%
- FY2014$71.3B-6.6%
- FY2013$76.3B-6.1%
- FY2012$81.3B-1.1%
- FY2011$82.2B-6.4%
- FY2010$87.8B-2.4%
- FY2009$90B+56.4%
- FY2008$57.6B-11.5%
- FY2007$65B-8.9%
- FY2006$71.4B+8.7%
- FY2005$65.6B-3.9%
- FY2004$68.3B+4.4%
- FY2003$65.4B+227.7%
- FY2002$20B+9.1%
- FY2001$18.3B+13.8%
- FY2000$16.1B+80.9%
- FY1999$8.89B+0.9%
- FY1998$8.81B+11.1%
- FY1997$7.93B+14.1%
- FY1996$6.95B+26.3%
- FY1995$5.51B+27.4%
- FY1994$4.32B+11.9%
- FY1993$3.87B-18.1%
- FY1992$4.72B-6.1%
- FY1991$5.03B-1.3%
- FY1990$5.09B+12.3%
- FY1989$4.54B+5.5%
- FY1988$4.3B+10.8%
- FY1987$3.88B+13.7%
- FY1986$3.42B+16.7%
- FY1985$2.93B—
Total Equity values are taken from Pfizer's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's latest reported total equity is $90.1B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Pfizer (PFE) most recent annual total equity stands at $86.5B (2025) – edged down 2.0% year-over-year.
Pfizer total equity compound annual growth for the 2020–2025 (5 years) window is +6.5%, with mixed annual results across the window.
Pfizer total equity peaked at $95.7B in 2022; the latest annual figure is $86.5B in 2025 (9.6% below peak).
Across the available history, total equity reached its high of $95.7B in 2022 and its low of $2.93B in 1985.
Pfizer Total Equity by Year
Pfizer Total Equity 2025: $86.5B
2025's total equity for Pfizer came in at $86.5B, edged down 2.0% below 2024.
Pfizer Total Equity 2024: $88.2B
Pfizer posted total equity of $88.2B in 2024, edged down 0.9% below 2023.
Pfizer Total Equity 2023: $89B
In 2023, Pfizer reported total equity of $89B, declined 6.9% below 2022.
Pfizer Total Equity 2022: $95.7B
Pfizer total equity in 2022 was $95.7B, grew 23.9% from 2021. This figure represents the highest annual value in the available history.
Pfizer Total Equity 2021: $77.2B
Pfizer total equity in 2021 was $77.2B.
See more financial history for Pfizer (PFE).
Sector peers by Total Equity
Healthcare peers of Pfizer (PFE), ranked by their latest total equity
| $94.1B | |
| $81.5B | |
| $53.4B | |
| $52.6B | |
| $30.5B | |
| $26.5B | |
| $8.66B | |
| -$3.27B |
- $94.1B
- $81.5B
- $52.6B
- $30.5B
- $26.5B
- $8.66B
- -$3.27B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks
- Dividend Profile6.93% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.